Johnson & Johnson Agrees $5.5bn Settlement for Talc Cancer Lawsuits

Johnson & Johnson has agreed to pay $5.5 billion to settle tens of thousands of lawsuits in the United States that allege its discontinued talc-based baby powder caused ovarian cancer. The pharmaceutical giant announced the landmark settlement on Monday, covering approximately 69,000 cases in US federal and state courts. This represents 99.75 percent of all outstanding talc-related cases in the country. The settlement marks a significant milestone in a legal battle that began as early as 2009, when consumers first filed lawsuits against the healthcare giant.

The company will finalize the settlement only after 95 percent of claimants in state or federal courts accept the terms. J&J plans to offer up to $3 billion next year, with no additional payments due before 2028. Legal firms representing the plaintiffs must approve the proposal before the company can proceed with the payout. Lawyers representing the plaintiffs have welcomed the settlement as a good resolution to the decade-long court battle.

Company Maintains Products Are Safe

Johnson & Johnson continues to deny that its talc-based products caused cancer, despite agreeing to the settlement. Erik Haas, the firm’s vice president of litigation, defended the company’s position while explaining the decision to settle. The company maintains its stance that the allegations lack merit and emphasizes its willingness to resolve the matter. Haas expressed confidence that the company would have “ultimately prevailed with further litigation” just as it has in the majority of cases heard in court to date.

“The proposed resolution allows the company to put this matter behind it and enable J&J to remain focused on its mission to develop medicines and devices that save lives,” Haas said in a statement.

The company has repeatedly stated that studies show talc is safe, does not contain asbestos, and does not cause cancer. Despite this position, J&J stopped selling talc-based baby powder in the US in 2020 and worldwide in 2023. The settlement represents a significant financial commitment for Johnson & Johnson. The company has maintained its position throughout the litigation that its products are safe.

History of Talc Litigation and Cancer Concerns

Talc is a soft mineral made of magnesium, silicon, oxygen, and hydrogen, known for its soapy feel and widespread use in baby powder. The substance was once a staple ingredient in cosmetics and baby products, but its use has declined as concerns rose over potential links to cancer. In 2024, the World Health Organization classified talc as “probably carcinogenic to humans”. This classification added weight to the mounting concerns about the mineral’s safety in consumer products.

Consumers and their survivors have filed lawsuits claiming that J&J’s talc products caused cancer due to raising concerns about potential cross-contamination during the mining process. The mineral is mined from the earth and is found in seams close to that of asbestos. Asbestos is a material known to cause cancer, which has fueled concerns about contamination. The company has faced thousands of lawsuits from individuals who developed ovarian cancer and mesothelioma after using the products.

Landmark Court Cases and Legal Victories

In 2016, a US jury ordered J&J to pay $72 million to the family of a woman who died of ovarian cancer, marking the first such case related to the use of the mineral in the country. Though the case was overturned a year later, claims against the company have multiplied since, with juries across the US awarding the plaintiffs. The legal battles have resulted in significant verdicts, with some juries ordering the company to pay substantial damages to affected families.

Earlier in July 2025, a federal court handed the firm a victory by questioning individual plaintiffs’ ability to show that talc was the direct cause of their ovarian cancer. This ruling provided J&J with legal grounds to argue that proving causation remains challenging for plaintiffs. Despite this victory, the company chose to pursue a comprehensive settlement to close the chapter on the litigation. The decision reflects the company’s desire to move past the controversy and focus on its core business operations.

UK Litigation Remains Outside Settlement Scope

The $5.5 billion deal does not cover the United Kingdom, where the largest product liability case in UK history is currently being adjudicated. Filed in October 2025, the UK case covers more than 7,000 potential claimants who allege that J&J knew that its talc could cause cancers, chiefly ovarian and mesothelioma, but continued to sell the product. The company denies this claim as well, maintaining its position that the products are safe and do not cause cancer.

The UK High Court has heard the case, which represents a separate and ongoing legal challenge for the pharmaceutical giant. The outcome of this case could have significant implications for product liability law in the United Kingdom. The scale of the UK litigation demonstrates that concerns about talc-based products extend beyond US borders. J&J’s former consumer health business, Kenvue, holds liability for Johnson’s baby powder outside North America.

Corporate Restructuring and Future Implications

Kenvue, which owns well-known brands including Band-Aid, Listerine, and Calpol, was spun off from J&J in 2022. This corporate restructuring means that Kenvue now bears responsibility for any talc-related claims arising from markets outside North America. In 2022, J&J announced it would stop making and selling its talc-based baby powder around the world. The decision followed years of mounting legal pressure and growing public concern about the product’s safety.

The settlement allows Johnson & Johnson to close a costly and damaging chapter in its corporate history. The agreement represents one of the largest product liability settlements in recent years and reflects the company’s determination to move forward. Legal experts view the settlement as a pragmatic decision that balances the company’s desire to avoid ongoing litigation costs with its commitment to maintaining its innocence. The pharmaceutical giant can now redirect its resources and attention to developing new medicines and medical devices without the burden of extensive talc litigation in the United States.